-
公开(公告)号：US11319381B2
公开(公告)日：2022-05-03
申请号：US16703343
申请日：2019-12-04
Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) , Universite Paul Sabatier Toulouse III , Institut Claudius Regaud
Inventor： Aurelien Olichon , Laura Keller , Gilles Favre , Nicolas Bery , Patrick Chinestra
Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
-
公开(公告)号：US20210292408A1
公开(公告)日：2021-09-23
申请号：US16319956
申请日：2017-07-28
Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) , Universite Paul Sabatier Toulouse III , Centre National de la Recherche Scientifique (CNRS) , Centre Hospitalier Universitaire de Toulouse , Institut Claudius Regaud
Inventor： Mary POUPOT , Loïc YSEBAERT , Marie TOSOLINI , Jean-Jacques FOURNIE , Pierre BROUSSET , Philippe ROCHAIX
IPC: C07K16/28 , G01N33/574
Abstract: The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.
-
公开(公告)号：US20210171658A1
公开(公告)日：2021-06-10
申请号：US16703343
申请日：2019-12-04
Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) , Universite Paul Sabatier Toulouse III , Institut Claudius Regaud
Inventor： Aurelien OLICHON , Laura KELLER , Gilles FAVRE , Nicolas BERY , Patrick CHINESTRA
Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
-
公开(公告)号：US10544210B2
公开(公告)日：2020-01-28
申请号：US15548578
申请日：2016-02-02
Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) , Universite Paul Sabatier Toulouse III , Institut Claudius Regaud
Inventor： Aurelien Olichon , Laura Keller , Gilles Favre , Nicolas Bery , Patrick Chinestra
Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
-
公开(公告)号：US20170174744A1
公开(公告)日：2017-06-22
申请号：US15310158
申请日：2015-05-12
Applicant: INSERM(INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE , INSTITUT CLAUDIUS REGAUD , UNIVERSITÉ PAULS SABATIER TOULOUSE III
Inventor： Bruno SEGUI , Nathalie ANDRIEU-ABADIE , Thierry LEVADE , Celine COLACIOS VIATGE , Philippe ROCHAIX , Florie BERTRAND , Herve BENOIST , Julia ROCHOTTE
IPC: C07K14/715 , G01N33/574 , C07K16/30 , A61K38/17 , C07K16/24
CPC classification number: C07K14/7151 , A61K38/1793 , A61K2039/505 , A61K2039/55 , C07K16/241 , C07K16/2878 , C07K16/3053 , C07K2317/21 , C07K2317/24 , C07K2317/76 , C07K2319/30 , G01N33/5743 , G01N2333/525 , G01N2333/70539
Abstract: The present invention relates to a TNFα blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF expression.
-
Patent Agency Ranking
公开(公告)号：US20220401436A1
公开(公告)日：2022-12-22
申请号：US17774997
申请日：2020-11-06
Applicant: INSERM (INSTITUTE NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ TOULOUSE III -PAUL SABATIER , INSTITUT CLAUDIUS REGAUD
Inventor： Olivier CALVAYRAC , Gilles FAVRE , Sarah FIGAROL
IPC: A61K31/4709 , A61K31/506 , A61P35/00 , A61K31/437 , A61K31/517 , A61K31/5377 , A61P11/00
Abstract: Resistance to kinase inhibitors exemplifies the greatest hindrance to effective treatment of cancer patients. Recent studies have suggested that the onset of said resistance might not only be explained by a drug selection of pre-existing resistant sub-clones as it what was generally assumed, but may also arise de novo from a small population of drug-tolerant cells (DTC) that initially resists the treatment by entering a slow cycling state. Thus, targeting these DTC should be a new promising approach to hamper the emergence of secondary resistance to kinase inhibitors. The inventors now demonstrate that farnesyltransferase (but not geranylgeranyl transferase) inhibition can prevent the emergence of said resistance in different oncogenic contexts. In particular, the inventors determined invitro the efficacy of farnesyltransferase inhibitor (i.e. Tipifarnib) in combination with erlotinib in several EGFR-mutated cell lines. They showed that the combination efficiently eliminated all drug tolerant cells, and fully prevented the emergence of resistant clones. Interestingly, similar results were observed in other oncogenic models such as ALK-translocated lung cancer cells or BRAF-mutated melanoma cells. Thus the present invention relates to use of farnesyl transferase inhibitors for the treatment of cancers that have acquired resistance to kinase inhibitors.
-
公开(公告)号：US20220143049A1
公开(公告)日：2022-05-12
申请号：US17593474
申请日：2020-03-19
Applicant: ONXEO , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE PAUL SABATIER TOULOUSE III , INSTITUT CLAUDIUS REGAUD
Inventor： FRANÇOISE BONO , GILLES FAVRE , OLIVIER CALVAYRAC
IPC: A61K31/6615 , C12N15/11 , C12N15/113 , A61K45/06 , A61K47/54
Abstract: The present invention relates to the combination of a Dbait molecule with a protein kinase inhibitor for treating cancer.
-
公开(公告)号：US11186634B2
公开(公告)日：2021-11-30
申请号：US16319956
申请日：2017-07-28
Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) , Universite Paul Sabatier Toulouse III , Centre National de la Recherche Scientifique (CNRS) , Centre Hospitalier Universitaire de Toulouse , Institut Claudius Regaud
Inventor： Mary Poupot , Loïc Ysebaert , Marie Tosolini , Jean-Jacques Fournie , Pierre Brousset , Philippe Rochaix
IPC: C07K16/28 , G01N33/50 , C12N5/09 , C12Q1/6886 , G01N33/574
Abstract: The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.
-
公开(公告)号：US20180022794A1
公开(公告)日：2018-01-25
申请号：US15548578
申请日：2016-02-02
Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) , Universite Paul Sabatier Toulouse III , Institut Claudius Regaud
Inventor： Aurelien OLICHON , Laura KELLER , Gilles FAVRE , Nicolas BERY , Patrick CHINESTRA
CPC classification number: C07K16/18 , A61K39/12 , C07K2317/22 , C07K2317/33 , C07K2317/569 , C07K2317/76 , C07K2317/80
Abstract: The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.
-
公开(公告)号：US20240301498A1
公开(公告)日：2024-09-12
申请号：US18257383
申请日：2021-12-13
Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , UNIVERSITÉ PAUL SABATIER TOULOUSE III , INSTITUT CLAUDIUS REGAUD
Inventor： Ataaillah BENHADDOU
IPC: C12Q1/6886 , G16B40/00 , G16H50/30
CPC classification number: C12Q1/6886 , G16B40/00 , G16H50/30 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156
Abstract: The present invention relates to the field of cancer diagnostic methods for classifying cancer patients using a measure of the distribution of markers of DNA structure alterations within tumor genomic DNA sequence. The inventors have observed, in sarcomas, such as leiomyosarcoma, that the distribution of breakpoints within a set of selected transcription-associated chromosomal instability elements and a set of selected replication-associated chromosomal instability elements can be used to classify patients in groups according to a level of genome instability, which may be representative of a cancer evolution, a risk of occurrence of metastasis, a survival rate, or a sensibility to a cancer treatment. The present invention also relates to machine learning and trained classifiers for classifying patients having a cancer based upon a distribution of genomic DNA structure alterations or variations.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.014 seconds)
